Consoli A, Formoso G, Baldassarre MPA, et al
Negative control of Listeria monocytogenes virulence genes by a diffusible autorepressor
These symptoms typically occur during treatment initiation or dose escalation and usually diminish over several weeks as the body adjusts to the medication
Phenotype definitions Using the information derived from the surveys, we defined phenotypes that aimed to capture aspects of drug efficacy and side effects
The peptides discussed are not approved for human consumption, clinical diagnosis, treatment, or any form of in-vivo use outside of controlled research settings
As of mid-2025, retatrutide is not approved by the MHRA or any other regulatory authority, and all dosing information derives exclusively from clinical trial protocols